🚀 VC round data is live in beta, check it out!
Poxel Valuation Multiples
Discover revenue and EBITDA valuation multiples for Poxel and similar public comparables like AlzeCure Pharma, Lipocine, Celyad Oncology, Pharma Equity Group and more.
Poxel Overview
About Poxel
Poxel SA is a biopharmaceutical company. It is focused on the development of novel treatments for metabolic diseases, including type 2 diabetes and liver diseases, such as nonalcoholic steatohepatitis (NASH) and rare disorders (ALD/AMN). It has developed a portfolio of drug candidates, including its candidates: Imeglimin, for the treatment of type 2 diabetes, and PXL770 and PXL065, for the treatment of NASH.
Founded
2009
HQ
Employees
37
Website
Sectors
Financials (FY)
EV
$32M
Poxel Financials
Poxel reported last fiscal year revenue of $8M and negative EBITDA of ($14M).
In the same fiscal year, Poxel generated $4M in gross profit, ($14M) in EBITDA losses, and had net loss of ($22M).
Revenue (LTM)
Poxel P&L
In the most recent fiscal year, Poxel reported revenue of $8M and EBITDA of ($14M).
Poxel expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $8M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $4M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 56% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($14M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (183%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (53%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($22M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (276%) | XXX | XXX | XXX |
| Net Debt | — | — | $19M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Poxel Stock Performance
Poxel has current market cap of $17M, and enterprise value of $32M.
Market Cap Evolution
Poxel's stock price is $0.33.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $32M | $17M | 5.7% | XXX | XXX | XXX | $-0.40 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPoxel Valuation Multiples
Poxel trades at 4.1x EV/Revenue multiple, and (2.3x) EV/EBITDA.
EV / Revenue (LTM)
Poxel Financial Valuation Multiples
As of April 18, 2026, Poxel has market cap of $17M and EV of $32M.
Equity research analysts estimate Poxel's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Poxel has a P/E ratio of (0.8x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $17M | XXX | $17M | XXX | XXX | XXX |
| EV (current) | $32M | XXX | $32M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 4.1x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (2.3x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (7.8x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 7.4x | XXX | XXX | XXX |
| P/E | — | XXX | (0.8x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (2.9x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Poxel Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Poxel Margins & Growth Rates
Poxel's revenue in the last fiscal year grew by 235%.
Poxel's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.2M for the same period.
Poxel Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 235% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (183%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (0%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 72% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 15% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 108% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Poxel Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Poxel | XXX | XXX | XXX | XXX | XXX | XXX |
| AlzeCure Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Lipocine | XXX | XXX | XXX | XXX | XXX | XXX |
| Celyad Oncology | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharma Equity Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Argenica Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Poxel M&A Activity
Poxel acquired XXX companies to date.
Last acquisition by Poxel was on XXXXXXXX, XXXXX. Poxel acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Poxel
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialPoxel Investment Activity
Poxel invested in XXX companies to date.
Poxel made its latest investment on XXXXXXXX, XXXXX. Poxel invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Poxel
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Poxel
| When was Poxel founded? | Poxel was founded in 2009. |
| Where is Poxel headquartered? | Poxel is headquartered in France. |
| How many employees does Poxel have? | As of today, Poxel has over 37 employees. |
| Is Poxel publicly listed? | Yes, Poxel is a public company listed on Euronext Paris. |
| What is the stock symbol of Poxel? | Poxel trades under POXEL ticker. |
| When did Poxel go public? | Poxel went public in 2015. |
| Who are competitors of Poxel? | Poxel main competitors are AlzeCure Pharma, Lipocine, Celyad Oncology, Pharma Equity Group. |
| What is the current market cap of Poxel? | Poxel's current market cap is $17M. |
| What is the current revenue of Poxel? | Poxel's last fiscal year revenue is $8M. |
| What is the current EV/Revenue multiple of Poxel? | Current revenue multiple of Poxel is 4.1x. |
| Is Poxel profitable? | No, Poxel is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.